You just read:

New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48

News provided by

Janssen Biotech Inc.

Dec 12, 2018, 07:00 ET